Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
NervGen Pharma ( (NGEN) ) has provided an announcement.
NervGen Pharma reported first-quarter 2026 results on May 18, highlighting progress on NVG-291 and its transition to a U.S.-focused capital markets presence. The company, now listed on Nasdaq under the ticker NGEN after delisting from the TSX Venture Exchange, ended the quarter with $16.6 million in cash and investments, higher R&D spending of $4.9 million, lower G&A of $2.7 million, and a narrowed net loss of $1.7 million due largely to a higher non-cash unrealized gain on warrant derivatives.
Operationally, NervGen completed a successful FDA End-of-Phase 2 meeting, securing alignment on RESTORE, its planned registrational trial of NVG-291 in chronic tetraplegia, with site activation underway and study initiation targeted for mid-2026. The company expects second-quarter 2026 results from independent gait analyses of its CONNECT SCI study, is preparing an indication-prioritization framework to expand NVG-291 into additional neurotraumatic and neurologic indications, and has bolstered its leadership team with senior hires in finance, regulatory affairs, and patient advocacy to support late-stage development and its Nasdaq listing.
The most recent analyst rating on (NGEN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the NGEN Stock Forecast page.
More about NervGen Pharma
NervGen Pharma Corp. is a Vancouver-based, clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions. Its lead candidate, NVG-291, a subcutaneous peptide targeting the CSPG-PTPσ pathway, has shown functional benefits in chronic tetraplegia and holds FDA Fast Track and EMA Orphan Drug designations.
Average Trading Volume: 168,318
Technical Sentiment Signal: Buy
Current Market Cap: $288.5M
For detailed information about NGEN stock, go to TipRanks’ Stock Analysis page.